Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2025-12-25 @ 11:27 PM
Study NCT ID:
NCT07241793
Status:
RECRUITING
Last Update Posted:
2025-12-18
First Post:
2025-09-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Sponsor:
Sun Yat-sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-11-20
Start Date Type:
ACTUAL
Primary Completion Date:
2028-07-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-07-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-24
First Submit QC Date:
None
Study First Post Date:
2025-11-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-11
Last Update Post Date:
2025-12-18
Last Update Post Date Type:
ESTIMATED